Monetary Data for the Fourth Quarter of 2021

• Income from exercise up 9% in 2021 to €1.4 million

• Gross sales of services and products down 8% in 2021 to €1.0 million

• Monetary sources providing monetary visibility by way of to the 4^th quarter of 2022

BAGNEUX, France, February 15, 2022–(BUSINESS WIRE)–Regulatory Information:

Genomic Imaginative and prescient (FR0011799907 – GV) (Paris:GV), a biotechnology firm that develops instruments and providers devoted to the evaluation and management of modifications within the genome, right this moment reported its income and money place at December 31, 2021¹.

Income for the fourth quarter and full 12 months 2021

Within the fourth quarter of 2021, gross sales of services and products totaled €374 thousand, a rise of 29% in contrast with the fourth quarter of 2020, with:

• €364 thousand that notably consists of the sale of a Fibervision® platform to the College of Florida (analysis market – LSR),

• €10 thousand in gross sales of the FSHD take a look at basically to La Timone hospital in France (in-vitro diagnostics market – IVD).

Whole income from exercise totaled €473 thousand within the fourth quarter of 2021, versus €296 thousand within the fourth quarter of 2020, a rise of 60%.

Whole income from exercise was €1,413 thousand over the 12 months to December 31, 2021, up 9% in contrast with the 12 months to December 31, 2020, and consisted of:

• gross sales of services and products of €994 thousand in 2021, down 8% in contrast with 2020, every of the 2 monetary years together with the sale of 1 platform,

• different income of €419 thousand over the 12 months to December 31, 2021, similar to Analysis Tax Credit score whose improve was a direct results of the Firm’s refocus on its Analysis and Growth actions in 2021.

Monetary construction

At December 31, 2021, Genomic Imaginative and prescient had money and money equivalents of €2.3 million. The Firm estimates that its obtainable money will allow it to finance its actions till Might 2022, with the extra money required to allow it to proceed its actions over the approaching 12 months estimated at €5 million.

Story continues

To be able to cowl its working capital necessities, the Firm put in place a financing line with Winance by way of the signing, on June 11, 2020, of an OCABSA (convertible notes with warrants) issuance contract. This contract offers for the issuance, to the advantage of Winance, of numerous €1 million tranches of OCABSA representing a most complete bond concern of €12 million over a 24-month interval.

The Firm thus has a remaining stability of €6 million on this financing line, in accordance with the traits indicated within the Prospectus granted visa quantity 21-028 by the AMF French inventory market authority on February 9, 2021 and below the contractual and authorized circumstances.

Based mostly on up to date gross sales progress and Analysis & Growth, Gross sales & Advertising and Basic & Administrative spending hypotheses, and on related working capital requirement assumptions, Genomic Imaginative and prescient may have the required sources to proceed its improvement by way of to the ultimate quarter of 2022.

The funding and progress financing necessities are primarily based on the next key strategic priorities:

• acceleration within the launch of excessive value-added functions onto the market;

• enchancment within the performances and design of latest merchandise to boost the gross sales supply;

• speedy strengthening of the groups, notably R&D and Gross sales groups, by recruiting gifted new employees.

Subsequent monetary communication*

* Indicative date, topic to alter. Publication will happen after the shut of the Euronext market.

***

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology firm growing services and products devoted to the evaluation (structural and useful) of genome modifications in addition to to the standard and security management of those modifications, particularly in genome modifying applied sciences and biomanufacturing processes. Genomic Imaginative and prescient proprietary instruments, primarily based on DNA combing know-how and synthetic intelligence, present sturdy quantitative measurements wanted to excessive confidence characterization of DNA alteration within the genome. These instruments are primarily used for monitoring DNA replication in cancerous cell, for early most cancers detection and the analysis of genetic ailments. Based mostly close to Paris, in Bagneux, GENOMIC VISION is a public listed firm listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For additional info, please go to www.genomicvision.com

***

Member of the CAC^® Mid & Small and CAC^® All-Tradable indexes

FORWARD LOOKING STATEMENT

This press launch incorporates implicitly or explicitly sure forward-looking statements regarding Genomic Imaginative and prescient and its enterprise. Such forward-looking statements are primarily based on assumptions that Genomic Imaginative and prescient considers to be affordable. Nonetheless, there could be no assurance that such forward-looking statements will likely be verified, which statements are topic to quite a few dangers, together with the dangers set forth within the “Danger Elements” part of the common registration doc filed with the AMF on February 9, 2021 below reference quantity R.21-002, obtainable on the internet web site of Genomic Imaginative and prescient (www.genomicvision.com) and to the event of financial circumstances, monetary markets and the markets through which Genomic Imaginative and prescient operates. The forward-looking statements contained on this press launch are additionally topic to dangers not but identified to Genomic Imaginative and prescient or not at present thought-about materials by Genomic Imaginative and prescient. The incidence of all or a part of such dangers might trigger precise outcomes, monetary circumstances, efficiency or achievements of Genomic Imaginative and prescient to be materially completely different from such forward-looking statements.

This press launch and the data contained herein don’t represent and shouldn’t be construed as a suggestion or an invite to promote or subscribe, or the solicitation of any order or invitation to buy or subscribe for Genomic Imaginative and prescient shares in any nation. The distribution of this press launch in sure international locations could also be a breach of relevant legal guidelines. The individuals in possession of this press launch should inquire about any native restrictions and adjust to these restrictions.

¹ Unaudited knowledge

View supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20220215005981/en/

Contacts

Genomic Imaginative and prescient
Dominique Remy-Renou
CEO
Tel.: +33 1 49 08 07 51
investisseurs@genomicvision.com

Ulysse Communication
Press Relations
Bruno Arabian
Tel.: +33 1 42 68 29 70
barabian@ulysse-communication.com

NewCap
Investor Relations
& Strategic Communications
Tel.: +33 1 44 71 94 94
gv@newcap.eu